Cochrane ENT has been awarded funding by the National Institute for Health Research (NIHR) to complete a suite of living systematic reviews investigating the effectiveness and safety of interventions to prevent and treat loss of smell after COVID-19 infection
Loss of sense of smell is a frequent symptom following COVID-19 infection. Although for a significant proportion of patients, the loss is only temporary and their sense of smell recovers relatively quickly, for others, the problem can persist and can have a major impact on quality of life.
Cochrane ENT has been awarded £34,011 of funding by the NIHR for a project on the ‘Prevention and treatment of persisting olfactory dysfunction after COVID-19 infection’.
Cochrane ENT will use the funding to complete a suite of Cochrane living systematic reviews to identify interventions that have been used to prevent or treat loss of smell following COVID-19 infection. The reviews will assess the effectiveness of interventions, as well as any adverse effects they may have. These living systematic reviews will be updated as and when new research becomes available.
This project is one of a number of COVID-19 projects that have been funded by the NIHR as part of its Recovery and Learning call, totalling £5.5m in funding, to help better manage current and future waves of the COVID-19 pandemic and investigate its long-term impacts on the health and care system beyond the acute phase.
You can find more information on the NIHR website